Francois Ferre, the co-CEO of contract service organization Althea Technologies, has joined the board of RNAi drug-delivery technology developer Traversa Therapeutics.
Ferre is also a member of San Diego Tech Coast Angels, a startup investment firm that contributed to Traversa’s recent Series A financing round (see related story, this issue).
Nastech Pharmaceutical this week announced that it has named seven people to the director’s strategic advisory board of its RNAi drugs spinout MDRNA.
Joining the board are Nastech board members Susan Bayh and Alexander Cross.
Also joining MDRNA’s strategic advisory board is Daniel Peters, who most recently served as president and CEO of global medical diagnostics at GE Healthcare; Nastech’s Chairman and CEO Steven Quay; James Rothman, who is currently a professor of chemical biology at Columbia University and was previously chief scientific advisor to GE Healthcare; Gregory Sessler, CFO of medical device firm Spiration and former senior vice president and CFO of Rosetta Inpharmatics; and Nastech board member Bruce Thaw.
Rosetta Genomics this week announced the establishment of its medical advisory board.
Joining the board as chairman is Moshe Hod, a professor of obstetrics and gynecology at the Helen Schneider Hospital for Women at the Rabin Medical Center, Tel-Aviv University.
Also joining the board are Harvey Pass, professor of cardiothoracic surgery and surgery at NYU School of Medicine; David Sidransky, a professor of oncology, otolaryngology, cellular and molecular medicine, urology, genetics, and pathology at Johns Hopkins University; Isaac Yaniv, chairman of the pediatric hematology oncology division at the Schneider Children's Medical Center; Jack Baniel, professor of urology at the Rabin Medical Center; Raphael Catane, a professor of oncology at the Chaim Sheba Medical Center, Tel Hashomer; and Maya Gottfried, a lung oncology researcher at the Meir Medical Center.